Six years ago, my doctor told me I had prostate cancer, and the news literally brought me to my knees. To say that I was scared at that moment is a big understatement. Nobody wants to hear the words, “You’ve got cancer,” and there are just no words to describe the devastation I felt. I…
Continue Reading
On August 13, 2015, Medicare approved coverage of the Prolaris® test for men diagnosed with low-risk and very low-risk prostate cancer. The decision is the culmination of years of scientific discovery, research and collaboration, and is an enormous step in improving patient care. Every day, 630 men in the United States are diagnosed with prostate…
Continue Reading
Myriad has led the industry in genetic testing for hereditary breast and ovarian cancer since the launch of BRACAnalysis® in 1996. Since then, we’ve changed the lives of countless patients and their families by helping them to understand their risk of disease. We also have introduced several other pioneering molecular diagnostic tests. In March 2010,…
Continue Reading
All of us at Myriad – from the executives and researchers, to the sales and customer service representatives – work hard because we know that, behind each and every Myriad test is a patient and a family with questions about disease. As the manager of patient education and advocacy, I am blessed to spend my…
Continue Reading
Data recently presented by Myriad Genetics’ prostate cancer prognostic test Prolaris is getting healthcare professionals and patients interested in learning more about how the multi-gene prognostic test can be used to gauge prostate cancer aggressiveness. Myriad Genetics presented data at the American Society of Clinical Oncology’s annual meeting from five studies involving Prolaris, all suggesting…
Continue Reading SALT LAKE CITY, March 5, 2013 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the Journal of Clinical Oncology demonstrated that its Prolaris test, which analyzes the expression level of 46 cell cycle progression genes, accurately predicted the elevated risk for prostate cancer recurrence in 413 men who had undergone a radical…
Continue Reading This past week Myriad Genetic Laboratories had the opportunity to present 2 posters at the Society for Urologic Oncologists that was held in Bethesda, MD. The first poster, DEVELOPMENT AND VALIDATION OF A MULTIVARIATE MODEL COMBINING CELL CYCLE PROGRESSION SCORE WITH CAPRA TO PREDICT PROSTATE CANCER MORTALITY IN A CONSERVATIVELY MANAGED COHORT was presented by…
Continue Reading SALT LAKE CITY, Nov. 28, 2012 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled “CCP Score Significantly Predicts PSA Failure After EBRT,” was presented on Wednesday, November 28th, 2012 at the Annual Meeting of the Society of Urological Oncology in Bethesda, Maryland. The study demonstrates that the Prolaris® test, which measures cell cycle progression (CCP) genes, significantly predicts PSA…
Continue Reading The Great Prostate Cancer Challenge (GPCC) is the premier men’s health race and event series in America. It is an exciting community activity that brings together athletes, cancer survivors, healthcare professionals, caretakers, family members and friends. The mission of GPCC is to raise awareness of Prostate Cancer, raise funds for Prostate Cancer research and provide…
Continue Reading This BRCA2 positive patient has had a mastectomy and prostatectomy. Yes, you read that correctly. Meet Robert, a male HBOC carrier and breast cancer survivor! I am 53 years old and yes, a breast cancer survivor!. I raised two sons as a single dad and have two grandchildren, with a third on the way. One…
Continue Reading